Recall(New to the series?)
Triple agonists activate all three incretin-related receptors: GLP-1R (appetite, insulin), GIPR (amplifies GLP-1 satiety signal), and GCGR (energy expenditure, liver fat). For the receptor-by-receptor breakdown, see The Receptor Game.
Triple agonism is the logical endpoint of the receptor-stacking approach: if single agonism reaches ~15% and dual agonism reaches ~21%, what happens when you activate all three receptors simultaneously?
The Phase 2 answer from retatrutide — 24.2% mean weight loss at 24 weeks — is the highest number ever recorded for a pharmacological intervention in obesity. No injectable drug, no oral drug, nothing outside bariatric surgery or surgery-adjacent devices has produced that number in a well-powered trial.
Why three receptors
Each receptor adds something the others don't:
GLP-1R — the foundation. Appetite suppression through the hypothalamus and brainstem, insulin secretion, gastric slowing. Every drug in this series activates GLP-1R.
GIPR — amplifies GLP-1's appetite signal through fat tissue and brain mechanisms. Tirzepatide proved this addition is real. At the dose and potency levels in retatrutide, GIPR co-agonism contributes meaningfully beyond GLP-1R alone.
GCGR — the component neither single nor GLP-1/GIP dual agonists provide. Raises resting energy expenditure, drives hepatic fat oxidation, adds CNS appetite effects. Theoretically addresses the metabolic rate adaptation that causes weight loss to plateau — the body's tendency to reduce caloric expenditure as it loses mass.
The three mechanisms operate in parallel from a single molecule binding all three receptors simultaneously.
The glucagon balance problem
GCGR activation raises blood glucose via hepatic glucose production, which partially opposes GLP-1's insulin-stimulating effect. Getting the right receptor potency ratio — enough glucagon engagement to raise metabolic rate without causing glucose excursions in non-diabetic patients — is the engineering challenge. Phase 2 data suggests it's solvable, but the titration schedule is slower than tirzepatide's.
Is there a ceiling above triple agonism?
The more likely direction is refining the ratio of existing targets or developing oral triple agonists — rather than adding a fourth receptor. Each additional target adds regulatory, tolerability, and formulation complexity that may not be worth the marginal gain.
Drug in this family
- Retatrutide — LY3437943, Eli Lilly — Phase 3, 24.2% weight loss in Phase 2
Summary(The triple agonist picture)
Triple agonism is the current efficacy frontier. One drug, retatrutide, with Phase 2 data at 24.2% — roughly 3–5 percentage points above tirzepatide's Phase 3 numbers. If Phase 3 TRIUMPH confirms that, triple agonism becomes the new ceiling the next generation will try to break.